Monopar Therapeutics (MNPR) Interest & Investment Income (2022 - 2026)

Monopar Therapeutics has reported Interest & Investment Income for 4 years, with the latest figure at -$65763.0 in Q3 2025.

• Quarterly Interest & Investment Income fell 166.2% year-over-year to -$65763.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $814696.0 (up 249.29% YoY) and the FY2023 annual result came in at $800998.0, up 27.12% from the prior year.
• Interest & Investment Income slipped to -$65763.0 in Q3 2025 per MNPR's latest filing, from $780769.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $800998.0 in Q4 2023 and troughed at -$65763.0 in Q3 2025.
• A 4-year average of $217561.3 and a median of $33645.0 in 2023 frame the typical range for Interest & Investment Income.
• The widest YoY moves for Interest & Investment Income: up 31846.36% in 2025, down 166.2% in 2025.
• Over 4 years, Interest & Investment Income stood at $630113.0 in 2022, then climbed by 27.12% to $800998.0 in 2023, then plunged by 87.6% to $99344.0 in 2024, then tumbled by 166.2% to -$65763.0 in 2025.
• According to Business Quant data, Interest & Investment Income over the past three periods registered -$65763.0, $780769.0, and $346.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.